North Brunswick, NJ – Distek, Inc., an industry leader in pharmaceutical laboratory testing instruments, accessories and validation services, is pleased to announce the availability of auto detection on the sensIR 3200 “Bathless” Disintegrator.
The sensIR 3200 utilizes “Patent Pending” Near Infrared to monitor and determine the disintegration endpoint for solid dosages. This state-of-the-art technology provides endpoint detection without the need of a modified fluted disk, therefore eliminating the accelerated disintegration and disparity the use of a fluted disk can cause with monographs not requiring disks.
“Unattended endpoint detection saves time and increases throughput” says Jeff Seely, Vice President of Sales & Business Development. “The release of the sensIR 3200 is another example of Distek’s innovation and leadership in the pharmaceutical testing market space. The use of IR to detect the presence of the tablet is a leap forward in disintegration testing providing reliable results and compliance with all monographs.”
For additional information contact Distek’s Corporate Office at +1 732 422 7585, by email at [email protected] or visit www.distekinc.com.
ABOUT DISTEK, INC.
Distek, Inc., headquartered in North Brunswick, NJ, is a leading manufacturer of pharmaceutical laboratory test equipment, specializing in dissolution products and services. Distek also provides solutions for UV fiber optics, media preparation, physical testing, disintegration, and validation services.
Contact:
Sean Gilmore
Distek, Inc.
121 North Center Drive
North Brunswick, NJ 08902
T: 732 422 7585
E: [email protected]